Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2026 10:15 ET | Source: Shoreline Recovery Center

Shoreline Recovery Center Experts Announce New Therapeutic Approach In Addiction Recovery

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- The disease of addiction has a domino effect – deeply impacting all relationships associated with the individual suffering in its grasp. The experts at...
March 10, 2026 08:30 ET | Source: Oragenics, Inc.

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent...
March 09, 2026 08:00 ET | Source: Cocrystal Pharma, Inc.

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No...
March 09, 2026 08:00 ET | Source: RTOERO

Entente Foundation announces Dr. Jennifer Watt as new chair in geriatric medicine

Toronto, Ontario, March 09, 2026 (GLOBE NEWSWIRE) -- The Entente Foundation (formerly RTOERO Foundation) has announced Dr. Jennifer Watt as the new Entente Education Canada Chair in Geriatric...
March 03, 2026 10:00 ET | Source: Persevere Therapeutics, Inc.

Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing

Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced its official...
February 25, 2026 08:00 ET | Source: Curanex Pharmaceuticals Inc

Curanex Provides Operational Update on Key Regulatory Milestones

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX)...
February 19, 2026 03:30 ET | Source: Custom Market Insights

Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Global ALS therapeutics market is expected to grow from USD 1.05B in 2025 to USD 1.96B by 2034 at 11.5% CAGR, driven by new therapies and rising worldwide.
February 18, 2026 08:03 ET | Source: Alembic Therapeutics

Alembic Therapeutics LLC Announces the Launch of PIVYA® (pivmecillinam)

Pivya® (pivmecillinam) Tablets, 185mg Now Available by Prescription in the United States BEDMINSTER, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics is pleased to announce the U.S....
February 11, 2026 09:15 ET | Source: Biofrontera Inc.

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial...
February 11, 2026 09:00 ET | Source: Eleos Health

CalMHSA Selects Eleos as Statewide AI Technology Partner for Behavioral Health

BOSTON and OAK BROOK, Ill. and SACRAMENTO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- After rigorous deliberation, Eleos, the leader in AI for behavioral health, today announced that the California...